Trexbio Prices IPO at $14, Raising $116.7M
Tom Rudovsky · Reported by Reuters
Sentiment
Neutral
Importance
7
Price
--
Mkt Cap
--
52W Low
--
52W High
--
52W Position
Off High
Rel. Volume
Market data snapshot near publication time
Summary
Trexbio, a clinical-stage biotechnology company, priced its initial public offering at $14 per share, selling 8,333,334 shares for gross proceeds of approximately $116.7 million. All shares are being offered by Trexbio. The pricing establishes the company's public market valuation and provides capital for its operations. The offering is expected to close on the standard settlement cycle, with shares beginning to trade on the Nasdaq under the ticker TRXB. This is the first public disclosure of the IPO terms.
This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.